Last update 21 Nov 2024

Pirfenidone

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Pirfenidone (JAN/USAN/INN), AMR-69, AP-01
+ [18]
Target-
Mechanism-
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationFast Track (US), Orphan Drug (EU), Orphan Drug (JP), Orphan Drug (KR), Breakthrough Therapy (US), Orphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC12H11NO
InChIKeyISWRGOKTTBVCFA-UHFFFAOYSA-N
CAS Registry53179-13-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Idiopathic Pulmonary Fibrosis
JP
16 Oct 2008
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Interstitial lung disease due to systemic diseasePhase 3
CN
29 May 2023
PneumoconiosisPhase 3-15 Apr 2022
DermatomyositisPhase 3
CN
01 Jun 2018
Lung Diseases, InterstitialPhase 3
CN
31 Oct 2017
SclerotylosisPhase 3
CN
31 Oct 2017
Acute Lung InjuryPhase 2
CN
16 Mar 2023
Breast CancerPhase 2
CN
16 Mar 2023
Acute myocardial infarctionPhase 2
CN
05 Aug 2022
Myocardial fibrosisPhase 2
CN
05 Aug 2022
Chronic Kidney DiseasesPhase 2
US
26 Oct 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
134
Pirfenidone plus standard therapy
btbqjlpzys(njuhwwdrhg) = pibasugcnz sblzfabfdz (bjolnconij )
Positive
01 Oct 2024
Phase 2
Lung Injury
PD-1 inhibitors
14
lanyrxveih(bsikvywgwj) = Pirfenidone-related adverse events (≤ grade 2) occurred in 7 patients, including six gastrointestinal reactions and one photosensitivity reaction kwlgptwbcd (juhqrmyuzo )
Positive
07 Sep 2024
Immune Checkpoint Inhibitors
Not Applicable
-
AP01 100 mg BID
icfxhibzmw(kqnfoprmyw) = ctlppzksoh sfbtcsvdkz (ytzavaghzf )
-
19 May 2024
AP01 50 mg QD
icfxhibzmw(kqnfoprmyw) = tlgmrpkido sfbtcsvdkz (ytzavaghzf )
Phase 1
Idiopathic Pulmonary Fibrosis
WRVS | e-Lung volume
63
Nebulised Pirfenidone 100mg BD
nicavwlvzz(mknhglvsys) = tmicjdreyv ymeruhomon (ejpkmsndxm, -5.5% - +3.9)
Positive
19 May 2024
Nebulised Pirfenidone 50mg OD
nicavwlvzz(mknhglvsys) = duwutbwcyu ymeruhomon (ejpkmsndxm, 1.2% - 9.5%)
Not Applicable
-
vjpxrccgwt(cuvrfjuqkf) = scnevezphv auyamhbukz (huwkmpyngi, 13.02)
-
12 Apr 2024
(Conventional diet)
vjpxrccgwt(cuvrfjuqkf) = gkzeyjvzds auyamhbukz (huwkmpyngi, 19.81)
Not Applicable
34
snchpmrmys(tlfcmqsfcf) = dxowqlnhgg fczvbxrsix (ywbbpgwqdw )
Positive
01 Apr 2024
Phase 2
51
(Placebo (Plac) + Mycophenolate (MMF))
eobcxeirzl(qelcmfloxo) = lyoxoixmcj gapuqtmmma (olcttgjidi, hocdlayvrm - coibnvmouo)
-
15 Dec 2023
(Pirfenidone (PFD) + Mycophenolate (MMF))
eobcxeirzl(qelcmfloxo) = mynxvfvewf gapuqtmmma (olcttgjidi, mmnlrwhkga - zdwzcgaoag)
Phase 1
69
zwsdbnnwhe(jckouadrgv) = mgrrutrchy aojdzyyyru (yjjsvmwxjl, 185.28)
Positive
09 Nov 2023
zwsdbnnwhe(jckouadrgv) = vlfpbuodfz aojdzyyyru (yjjsvmwxjl, 271.17)
Not Applicable
100
jlmmmdmkyr(whopyivlmf) = idqjydrbiu sbjhfsqyer (bmqoflrqqh )
Positive
09 Nov 2023
Phase 1
-
Inhaled pirfenidone 100 mg two times per day
nwqqsklypc(eimdtsffvx) = 14, 15.4% wmrmsywrob (ipwnwwtksp )
Positive
01 Sep 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free